Author:
Gaffuri M.,Cristofaletti A.,Mansoldo C.,Biban P.
Reference13 articles.
1. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension;Abman;Am J Resp Crit Care Med,2013
2. U.S. Food and Drug Administration [Internet]. FDA Drug Safety Communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension. 2012 [cited 30 Aug 2012]. http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm
3. Management of ischemic optic neuropathies;Hayreh;Indian J Ophthalmol,2011
4. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature;Azzouni;J Sex Med,2011
5. Ischemic optic neuropathy in a child;Sivaswamy;Pediatr Neurol,2007
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献